What does 'shelf life' actually mean for a cannabinoid medicine?

Shelf life is the period during which a formulation is expected to remain within its approved specification — meaning the concentrations of active compounds, physical appearance, microbial limits, and other quality attributes stay within the ranges confirmed by stability data. It's not a guess; it's derived from real-time and accelerated stability studies conducted under defined conditions, as outlined in the ICH Q1A(R2) guideline that the TGA references for prescription medicines.

Does CBD really convert to THC over time?

Under certain conditions — particularly heat and low pH — CBD can undergo cyclisation to form THC. This is a documented chemical reaction, not a theoretical concern. It's one reason why formulation conditions (pH, temperature) and storage requirements matter for products marketed as non-psychoactive. In a well-formulated, properly stored product, the conversion is expected to be negligible within the validated shelf life, but this should be confirmed by forced degradation studies.

Why are terpene levels harder to maintain than cannabinoid levels during storage?

Most terpenes are monoterpenes or sesquiterpenes with significantly higher volatility than cannabinoids. They can evaporate through packaging that isn't perfectly sealed, and they oxidise readily on contact with air. Full-spectrum and broad-spectrum formulations therefore require more stringent packaging and storage conditions than cannabinoid isolates, and ideally stability studies that specifically track terpene profiles over time — not just the cannabinoid fraction.

Do Australian regulations require stability data for cannabinoid medicines?

Yes. Products listed or registered on the Australian Register of Therapeutic Goods (ARTG) must have stability data supporting their labelled shelf life, in line with TGA guidance that references ICH Q1A(R2). Products supplied under the Special Access Scheme or via an Authorised Prescriber pathway must be manufactured under GMP and meet quality standards that include stability requirements. The TGA's guidance documents set out these expectations explicitly.

What is CBN and why does it matter in stability testing?

CBN (cannabinol) is a primary oxidative degradation product of THC. As THC ages and is exposed to oxygen, it gradually converts to CBN. Analytical chemists use the CBN-to-THC ratio in a sample as one indicator of how much degradation has occurred, particularly in seized or archival cannabis material. In a medicinal formulation context, CBN accumulation above specified limits is a sign that the product has moved outside its specification and the shelf life has effectively ended.

Stability Testing and Shelf-Life Studies

By Tom Whitfield · 26 June 2026 · 7 min read

a close up of a person holding a glass with a substance inside of it

The question nobody asks until something smells wrong

Forty-seven. That's how many peer-reviewed papers I pulled last quarter trying to answer one deceptively simple question: how long does a cannabis-based formulation stay chemically what it says it is? I expected a neat answer. What I got was a rabbit warren of degradation pathways, packaging variables, and regulatory frameworks that differ depending on whether a product is sitting on an ARTG-registered shelf or moving through the Special Access Scheme.

Stability testing is the part of pharmaceutical science that most educational resources skip over in favour of the more photogenic topics. Fair enough, maybe. But it matters enormously for understanding what a formulation actually contains at the point of use, which is a precondition for understanding almost anything else about it.

What stability testing actually measures

At its core, a stability study asks: under defined conditions of temperature, humidity, and light, does a formulation maintain its identity, potency, purity, and physical characteristics within specified limits over a defined period?

The International Council for Harmonisation (ICH) guidelines , particularly ICH Q1A(R2) , set the standard framework used globally, including by the TGA when evaluating medicinal products for ARTG listing. Real-time stability studies run at 25 °C / 60% relative humidity (long-term) and 40 °C / 75% RH (accelerated). Intermediate conditions (30 °C / 65% RH) are used in some zones. Australia sits in ICH Climatic Zone IV, which historically pushed accelerated studies toward the harsher end of those parameters.

For conventional pharmaceuticals, this is well-trodden ground. For cannabinoid-containing medicines, it is considerably less so. The published literature on cannabinoid stability is growing but remains thin compared to, say, small-molecule oncology drugs, and a lot of what exists doesn't meet the methodological standards ICH Q1A demands.

How cannabinoids degrade

Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most studied, partly because they're the ones regulators and researchers have had reason to track longest. Both are terpenophenolic compounds with multiple sites vulnerable to oxidation and isomerisation.

CBD oxidises to form a range of quinone and epoxide products. Under acidic conditions , or heat; it can cyclise to THC, which has obvious regulatory implications for a product labelled as non-psychoactive. That conversion is well-documented in the chemistry literature and is one reason why formulation pH and storage temperature are not minor footnotes. THC, for its part, oxidises progressively to CBN (cannabinol). CBN accumulation is often used as a proxy marker for THC degradation in aged samples. A 2016 study by Lindholst published in the journal Forensic Science International examined cannabis resin samples and found CBN/THC ratios useful as degradation indicators, though extrapolating those findings to formulated medicinal products requires care.

The minor cannabinoids are less well characterised. CBG and CBC have their own oxidative vulnerabilities, and there is almost no long-term stability data in the peer-reviewed literature for very minor compounds like CBDV or THCV. That's a genuine gap. I'd argue it's actually the most underfunded corner of cannabinoid analytical science right now, not because it's complicated in principle, but because there's been little commercial incentive to fund multi-year studies on minor cannabinoids until recently.

Terpenes: the more volatile problem

Terpenes are, almost by definition, more volatile than cannabinoids. The monoterpenes, limonene, alpha-pinene, linalool; have relatively low boiling points and evaporate readily through inadequate packaging. The sesquiterpenes, beta-caryophyllene, humulene, nerolidol, are heavier and somewhat more stable, but still susceptible to oxidation.

This matters because of the entourage effect hypothesis: the idea that the full chemical complement of a cannabis preparation, including its terpene fraction, contributes to its overall pharmacological profile. Whether or not you accept the entourage effect hypothesis fully, a product that has lost most of its terpene fraction through volatilisation is chemically different from a freshly manufactured batch. Full-spectrum and broad-spectrum formulations are therefore more stability-sensitive than a cannabinoid isolate, which has fewer components to lose.

I spent a wet Tuesday afternoon last year cross-referencing terpene volatility data against published cannabis oil stability studies. Honestly, it was one of those afternoons that reminds you why reference work takes as long as it does; the data sets rarely align cleanly. Between the birdwatching app notifications I kept muting and the pile of old botanical pharmacy texts I'd dragged home from a Paddington secondhand shop on Given Terrace, I managed to build a half-decent comparison table. The short version: monoterpene loss in poorly sealed formulations can be substantial within six months at ambient temperature.

Formulation type changes everything

An oral oil solution behaves very differently in stability terms from a solid dosage form, a nasal spray, or an inhaled preparation. Oxygen headspace in a bottle, for instance, is a primary driver of cannabinoid oxidation. Nitrogen-flush packaging and light-resistant amber glass are practical responses to that problem, both are standard in Good Manufacturing Practice (GMP)-compliant manufacturing.

Water activity in emulsified or aqueous formulations introduces microbial stability considerations that anhydrous oils don't face. The physicochemical stability of cannabinoids in lipid-based delivery systems, where particle size and droplet distribution can shift over time; is a separate area of study again. Bioavailability is partly a function of formulation integrity, so physical instability (creaming, coalescence, phase separation) isn't just an aesthetic issue; it can alter how the formulation behaves entirely.

GMP-manufactured medicines in Australia are required to have stability data supporting their labelled shelf life before they can be listed or registered on the ARTG or supplied under the SAS. The TGA's guidance on stability testing for prescription medicines references ICH Q1A(R2) directly. That's the floor. What's actually submitted in dossiers varies, and the TGA's published guidance notes that accelerated data alone is insufficient for establishing a final shelf life claim.

Photodegradation and the light problem

Cannabinoids are photosensitive. Ultraviolet and visible light both drive degradation reactions, CBD and THC have documented photodegradation pathways, and some studies suggest light is a faster degrader than heat under realistic storage conditions. This is why packaging specifications in stability protocols include a photostability study (ICH Q1B is the relevant guideline), and why products are typically specified for storage away from direct light.

It sounds obvious. But the practical implication for standardised extract products is that an unlabelled or poorly packaged preparation left on a bench, or in a bag in a car, is accumulating degradation products at a rate that no shelf-life study was designed to account for.

What a stability report should actually contain

A credible stability dossier for a cannabinoid medicine will include: a defined testing schedule (0, 3, 6, 9, 12, 18, 24 months minimum for long-term); validated analytical methods for each analyte of interest (cannabinoid profile, terpene profile if relevant, degradation products, appearance, pH, viscosity, microbial limits as applicable); defined acceptance criteria tied to the product specification; and batch data from at least three primary batches manufactured at production scale. Forced degradation studies, deliberately stressing samples with heat, acid, base, oxidants, and light; are used to identify likely degradation pathways and confirm that the analytical methods detect them.

That's a substantial analytical programme. It is also exactly why GMP-manufactured, ARTG-listed or SAS-approved products carry a different analytical warranty than unregistered preparations. The data either exists or it doesn't.

Pharmacokinetics studies, how a compound moves through the body after administration, generally use freshly manufactured material. Whether stability-induced chemical changes affect pharmacokinetic behaviour is a question that has barely been asked in the cannabinoid literature. That gap will eventually need closing.

Sources

, Tom Whitfield, Health librarian, references & fact-checking

Common questions

What does 'shelf life' actually mean for a cannabinoid medicine?: Shelf life is the period during which a formulation is expected to remain within its approved specification — meaning the concentrations of active compounds, physical appearance, microbial limits, and other quality attributes stay within the ranges confirmed by stability data. It's not a guess; it's derived from real-time and accelerated stability studies conducted under defined conditions, as outlined in the ICH Q1A(R2) guideline that the TGA references for prescription medicines.
Does CBD really convert to THC over time?: Under certain conditions — particularly heat and low pH — CBD can undergo cyclisation to form THC. This is a documented chemical reaction, not a theoretical concern. It's one reason why formulation conditions (pH, temperature) and storage requirements matter for products marketed as non-psychoactive. In a well-formulated, properly stored product, the conversion is expected to be negligible within the validated shelf life, but this should be confirmed by forced degradation studies.
Why are terpene levels harder to maintain than cannabinoid levels during storage?: Most terpenes are monoterpenes or sesquiterpenes with significantly higher volatility than cannabinoids. They can evaporate through packaging that isn't perfectly sealed, and they oxidise readily on contact with air. Full-spectrum and broad-spectrum formulations therefore require more stringent packaging and storage conditions than cannabinoid isolates, and ideally stability studies that specifically track terpene profiles over time — not just the cannabinoid fraction.
Do Australian regulations require stability data for cannabinoid medicines?: Yes. Products listed or registered on the Australian Register of Therapeutic Goods (ARTG) must have stability data supporting their labelled shelf life, in line with TGA guidance that references ICH Q1A(R2). Products supplied under the Special Access Scheme or via an Authorised Prescriber pathway must be manufactured under GMP and meet quality standards that include stability requirements. The TGA's guidance documents set out these expectations explicitly.
What is CBN and why does it matter in stability testing?: CBN (cannabinol) is a primary oxidative degradation product of THC. As THC ages and is exposed to oxygen, it gradually converts to CBN. Analytical chemists use the CBN-to-THC ratio in a sample as one indicator of how much degradation has occurred, particularly in seized or archival cannabis material. In a medicinal formulation context, CBN accumulation above specified limits is a sign that the product has moved outside its specification and the shelf life has effectively ended.